Spironolactone May Help Treat Chronic Alcoholism

Scherger, Joseph E. MD, MPH

Core Faculty, Eisenhower Health Family Medicine Residency Program, Eisenhower Health Center, La Quinta, CA; Clinical Professor, Keck School of Medicine, University of Southern California, Los Angeles

Financial Disclosure: Dr. Stephen Brunton, physician editor, reports he is on the speakers bureau for AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, and Novo Nordisk; and is a retained consultant for Abbott Diabetes Care, AstraZeneca, Bayer, GSK, and Novo Nordisk. The relevant financial relationships listed have been mitigated. None of the remaining planners or authors for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Internal Medicine Alert 44(22):p 169-170, November 30, 2022.

SYNOPSIS: Both animal and human studies suggest spironolactone might be a new agent for helping patients with alcohol use disorder cut their intake.

SOURCE: Farokhnia M, Rentsch CT, Chuong V, et al. Spironolactone as a potential new pharmacotherapy for alcohol use disorder: Convergent evidence from rodent and human studies. Mol Psychiatry 2022; Sep 20. doi: 10.1038/s41380-022-01736-y. [Online ahead of print].